CCDC102B

Across TCGA pan-cancer cohorts, CCDC102B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC102B data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CCDC102B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC102B expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

LIHC, SKCM, and PRAD are the cancer types where CCDC102B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
SKCM	OS	Median	II,III,IV	0.937	0.716	.020	9	view →
PRAD	DFS	Median	All	0.111	0.886	<.001	8	view →
ESCA	DFS	Median	III,IV	0.080	0.442	<.001	6	view →
UCEC	DFS	Median	All	0.949	0.828	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCDC102B–LIHC (DFS)

Open the LIHC breakdown →